Janus Henderson Group
ESLA icon

Janus Henderson Group’s Estrella Immunopharma ESLA Stock Holding History

Janus Henderson Group’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-17,335
Closed -$178K – 2697
2022
Q4 		$178K Sell
17,335
-17,335
-50% -$176K ﹤0.01% 2219
2022
Q3 		$350K Buy
34,670
+17,335
+100% +$174K ﹤0.01% 2117
2022
Q2 		$174K Hold
17,335
– – ﹤0.01% 2349
2022
Q1 		$173K Buy
+17,335
New +$173K ﹤0.01% 2472

Other funds holding ESLA

HHGC
Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Janus Henderson Group's ESLA Position: Q1 2023 in Review

Janus Henderson Group sold out of Estrella Immunopharma (ESLA) in Q1 2023, closing a stake of 17,335 shares — an estimated $178K sold.

Janus Henderson Group first reported a position in ESLA in Q1 2022 and held it in 4 quarters. The position peaked at $350K in Q3 2022. 8 funds tracked by Wall St. Rank hold ESLA as of Q1 2023.

  • Janus Henderson Group reported no remaining Estrella Immunopharma position as of Q1 2023 after selling out during the quarter.
  • Janus Henderson Group sold 17,335 Estrella Immunopharma shares in Q1 2023, an estimated $178K.
  • Janus Henderson Group first reported a position in Estrella Immunopharma in Q1 2022 and held it in 4 quarters.
  • Janus Henderson Group's Estrella Immunopharma position peaked at $350K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2023.

Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.